These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1403 related items for PubMed ID: 15492298

  • 1. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K, Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees.
    Circulation; 2004 Oct 26; 110(17):2618-26. PubMed ID: 15492298
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin inhibition in heart failure.
    McMurray JJ.
    J Renin Angiotensin Aldosterone Syst; 2004 Sep 26; 5 Suppl 1():S17-22. PubMed ID: 15526237
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB.
    J Hypertens Suppl; 2006 Mar 26; 24(1):S3-7. PubMed ID: 16601570
    [Abstract] [Full Text] [Related]

  • 4. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
    McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA, CHARM Investigators and Committees.
    Lancet; 2003 Sep 06; 362(9386):767-71. PubMed ID: 13678869
    [Abstract] [Full Text] [Related]

  • 5. [Clinical study of the month. The CHARM study].
    Kulbertus H.
    Rev Med Liege; 2003 Oct 06; 58(10):646-52. PubMed ID: 14677527
    [Abstract] [Full Text] [Related]

  • 6. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
    Cohen-Solal A, McMurray JJ, Swedberg K, Pfeffer MA, Puu M, Solomon SD, Michelson EL, Yusuf S, Granger CB, CHARM Investigators.
    Eur Heart J; 2008 Dec 06; 29(24):3022-8. PubMed ID: 18987098
    [Abstract] [Full Text] [Related]

  • 7. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.
    Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Yusuf S.
    Am Heart J; 2006 May 06; 151(5):985-91. PubMed ID: 16644318
    [Abstract] [Full Text] [Related]

  • 8. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 06; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 9. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
    Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K, CHARM Investigators and Committees.
    Lancet; 2003 Sep 06; 362(9386):772-6. PubMed ID: 13678870
    [Abstract] [Full Text] [Related]

  • 10. The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Pocock S, Wang D, Wilhelmsen L, Hennekens CH.
    Am Heart J; 2005 May 06; 149(5):939-43. PubMed ID: 15894981
    [Abstract] [Full Text] [Related]

  • 11. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, Puu M, Yusuf S, Pfeffer MA, CHARM Investigators.
    J Am Coll Cardiol; 2006 May 16; 47(10):1997-2004. PubMed ID: 16697316
    [Abstract] [Full Text] [Related]

  • 12. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
    Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ, Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators.
    Circulation; 2006 Feb 07; 113(5):671-8. PubMed ID: 16461840
    [Abstract] [Full Text] [Related]

  • 13. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    McMurray JJ, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL, Earle S, Olofsson B, Ostergren J, Yusuf S, Swedberg K, Pfeffer MA, CHARM Investigators.
    Am Heart J; 2006 May 07; 151(5):985-91. PubMed ID: 16644319
    [Abstract] [Full Text] [Related]

  • 14. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pocock S, Pfeffer MA.
    Circulation; 2004 Oct 12; 110(15):2180-3. PubMed ID: 15466644
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA, McMurray JJ, Puu M, Solomon SD, Olofsson B, Granger CB, Yusuf S, Michelson EL, Swedberg K, Pfeffer MA, CHARM Investigators.
    Eur J Heart Fail; 2008 Feb 12; 10(2):157-63. PubMed ID: 18242128
    [Abstract] [Full Text] [Related]

  • 16. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.
    Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, CHARM Investigators and Committees.
    Lancet; 2003 Sep 06; 362(9386):777-81. PubMed ID: 13678871
    [Abstract] [Full Text] [Related]

  • 17. [CHARM study--new strategy for the treatment of heart failure].
    Hasegawa H, Komuro I.
    Nihon Rinsho; 2004 May 06; 62(5):995-1002. PubMed ID: 15148833
    [Abstract] [Full Text] [Related]

  • 18. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.
    Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S, CHARM Investigators and Committees.
    Lancet; 2003 Sep 06; 362(9386):759-66. PubMed ID: 13678868
    [Abstract] [Full Text] [Related]

  • 19. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program.
    Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB, Dunlap ME, Solomon SD, Hainer JW, Olofsson B, Michelson EL, Pfeffer MA, CHARM Program Investigators.
    J Am Coll Cardiol; 2007 Nov 13; 50(20):1959-66. PubMed ID: 17996561
    [Abstract] [Full Text] [Related]

  • 20. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.
    Demers C, McMurray JJ, Swedberg K, Pfeffer MA, Granger CB, Olofsson B, McKelvie RS, Ostergren J, Michelson EL, Johansson PA, Wang D, Yusuf S, CHARM Investigators.
    JAMA; 2005 Oct 12; 294(14):1794-8. PubMed ID: 16219883
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.